A Study Utilizing Escitalopram in Glioma Patients

• Status: Recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This pilot study will include grade IV glioma patients treated with SSRIs during approximately a 17 week study period. Changes in cognition and evaluation of psychosocial factors from baseline to after 17 weeks of treatment with SSRI study drug will be calculated.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nicole Shonka
• Treatments: Citalopram; Dexetimide

Criteria

Inclusion Criteria:

• Patient with pathologically proven diagnosis of Grade IV glioma

• Patients planning to receive chemotherapy and/or radiation for newly diagnosed disease

• Performance status ECOG 0-2 or equivalent

• Patients must be age ≥19 years

• Life expectancy greater than 6 months

• Written informed consent to participate in the study.

Exclusion Criteria:

• Hemifield defects (as this obscures visual field necessary to participate in all tests)

• Inability to undergo MRI

• Severe renal impairment defined as GFR<30 mL/minute

• Screen positive for depression or anxiety

• Already taking an anti-depressant (SSRI or NSRI)

• Have problems tolerating past treatment with SSRI or NSRIs

• Females of childbearing potential must have a negative urine pregnancy test at the study enrollment.

• Female patients must be either postmenopausal, free from menses for ≥2 years, surgically sterilized, or willing to use two adequate barrier forms of contraception